Amedisys Inc (NASDAQ:AMED) – Equities researchers at Jefferies Financial Group boosted their FY2020 earnings estimates for shares of Amedisys in a report issued on Wednesday, July 31st, according to Zacks Investment Research. Jefferies Financial Group analyst B. Tanquilut now forecasts that the health services provider will earn $4.95 per share for the year, up from their prior forecast of $4.85. Jefferies Financial Group has a “Buy” rating and a $150.00 price objective on the stock.
A number of other analysts also recently commented on AMED. ValuEngine upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, June 22nd. BidaskClub raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 26th. Oppenheimer increased their price target on shares of Amedisys from $140.00 to $150.00 in a research note on Thursday, August 1st. Raymond James increased their price target on shares of Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Monday, July 15th. Finally, Barclays increased their price target on shares of Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a research note on Monday, August 5th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $135.90.
AMED stock traded down $0.46 during mid-day trading on Monday, reaching $132.56. The company’s stock had a trading volume of 199,748 shares, compared to its average volume of 416,390. The stock has a market cap of $4.27 billion, a PE ratio of 36.52, a P/E/G ratio of 1.94 and a beta of 1.42. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 0.58. Amedisys has a fifty-two week low of $97.38 and a fifty-two week high of $141.98. The company’s 50 day moving average is $129.35 and its two-hundred day moving average is $123.78.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, July 31st. The health services provider reported $1.21 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.24. The firm had revenue of $492.98 million during the quarter, compared to the consensus estimate of $489.66 million. Amedisys had a net margin of 6.84% and a return on equity of 27.23%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 EPS.
Several institutional investors and hedge funds have recently made changes to their positions in AMED. Price T Rowe Associates Inc. MD raised its holdings in shares of Amedisys by 286.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,349,405 shares of the health services provider’s stock valued at $163,831,000 after purchasing an additional 999,892 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in shares of Amedisys by 937.5% in the second quarter. William Blair Investment Management LLC now owns 988,533 shares of the health services provider’s stock valued at $120,018,000 after acquiring an additional 893,253 shares in the last quarter. Riverbridge Partners LLC purchased a new stake in shares of Amedisys in the second quarter valued at about $80,465,000. Norges Bank purchased a new stake in shares of Amedisys in the fourth quarter valued at about $68,342,000. Finally, Eagle Asset Management Inc. purchased a new stake in shares of Amedisys in the second quarter valued at about $35,359,000. Institutional investors and hedge funds own 88.23% of the company’s stock.
In other Amedisys news, insider David L. Kemmerly sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $113.48, for a total value of $567,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey A. Rideout sold 1,263 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $114.33, for a total transaction of $144,398.79. Following the completion of the transaction, the director now directly owns 5,554 shares of the company’s stock, valued at approximately $634,988.82. The disclosure for this sale can be found here. Insiders sold a total of 51,427 shares of company stock valued at $6,298,052 in the last three months. 2.90% of the stock is currently owned by corporate insiders.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.